Quarterly report [Sections 13 or 15(d)]

Significant Accounting Policies and Estimates (Tables)

v3.26.3
Significant Accounting Policies and Estimates (Tables)
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents

    September 30,     September 30,  
    2026     2025  
Cash   $ 278     $ 938  
Restricted cash     380       920  
Total cash and restricted cash shown in the statement of cash flows   $ 658     $ 1,858  
Schedule of Fair Value of Derivative Liabilities

    Level 1     Level 2     Level 3     Total  
Derivative liability as of September 30, 2026 ($ in thousands)   $ –     $ –     $ 5,096     $ 5,096  
Schedule of Level 3 Roll-forward for Derivative Liabilities

Level 3 Roll-forward

 

    Amount ($ in thousands)  
Balance at January 1, 2026   $ –  
Initial recognition of derivative liability     11,187  
Changes in fair value     (6,091 )
Balance at September 30, 2026   $ 5,096  

Schedule of Disaggregated Revenue by Sales Type

Disaggregated revenue by sales type ($ in thousands):

    2026     2025  
    Three Months  
    September 30,  
    2026     2025  
Contract manufacturing   $ 736     $ 907  
Custom and white label finished goods manufacturing     -       -  
Consumer branded products     1,476       1,918  
Medical devices/other     86       109  
Biomaterial products     881       -  
Total   $ 3,179     $ 2,934  

 

    2026     2025  
    Nine Months Ended  
    September 30,  
    2026     2025  
Contract manufacturing   $ 2,690     $ 2,718  
Custom and white label finished goods manufacturing     -       27  
Consumer branded products     4,854       5,584  
Medical devices/other     276       296  
Biomaterial products     1,695       -  
Total   $ 9,515     $ 8,625